Sosei Group Corp. | Cash Flow

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
738
1,301
3,297
12,483
3,702
Depreciation, Depletion & Amortization
20
98
926
923
1,028
Other Funds
349
-
686
4,366
666
Funds from Operations
588
1,644
2,304
13,555
3,315
Changes in Working Capital
224
1,552
2,167
699
1,148
Net Operating Cash Flow
363
92
4,471
12,856
2,167
Capital Expenditures
11
88
130
332
968
Sale of Fixed Assets & Businesses
-
-
-
-
378
Purchase/Sale of Investments
-
-
-
500
5,547
Net Investing Cash Flow
315
22,018
337
2,327
6,148
Cash Dividends Paid - Total
-
-
135
-
-
Issuance/Reduction of Debt, Net
-
19,835
11,200
2,000
2,140
Net Financing Cash Flow
4,375
19,864
863
6,310
22,641
Net Change in Cash
4,677
1,641
4,495
3,832
14,382
Free Cash Flow
353
4
4,341
12,524
3,047
Net Assets from Acquisitions
-
21,676
-
1,188
-
Change in Capital Stock
4,724
29
12,884
55
21,167
Exchange Rate Effect
254
421
502
387
56
Other Uses
305
254
207
306
11

About Sosei Group

View Profile
Address
PMO Hanzomon, 11/F
Tokyo Tokyo 102
Japan
Employees -
Website http://www.sosei.com
Updated 07/08/2019
Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). Its proprietary StaR (Stabilised Receptor) technology and structure-based drug design (SBDD) platform enables development of drugs for highly validated, yet historically undruggable or challenging GPCRs. The company has multiple programs targeting Alzheimer's disease, schizophrenia, immuno-oncology, migraine, metabolic disease and other rare and specialty indications.